Summary Monoclonal antibody 4E3 directed against a glycosylated surface protein on human ovarian teratocarcinoma cells (CRL-1572 cell line) was conjugated to bovine carboxypeptidase A (CPA) using a 3400 Da polyethylene glycol chain bearing an N-hydroxysuccinimide group at both ends. The conjugate preparation was purified by fast protein liquid chromatography on a Superose 12/30 HR column. The 4E3 -CPA conjugate was recovered in the third fraction by SDS-PAGE analysis. The specific binding of the 4E3 -CPA conjugate to CRL-1572 cells was confirmed by a FACS analysis and the enzymatic activity of the conjugate remained while tested with hippuryl-L-phenylalanine. In vitro cytotoxic assays on CRL-1572 cells showed that the prodrug methotrexate-phenylalanine (MTX-Phe) alone was non-toxic (ID50> 1000 ng ml-1) but was selectively converted to MTX when the cells were pretreated with 50 ig ml-1 4E3 -CPA conjugate, which enhanced considerably the pharmacological activity of the prodrug with an ID50 of 70 ng ml-l. The co-culture assays with CRL-1572 and MRC-5 cells (human normal lung diploid fibroblast cell lines) demonstrated the specificity of the 4E3-CPA conjugate for the CRL-1572 cells since no cytotoxicity was observed on the MRC-5 cells. When both cell lines were mixed in ratios ranging from 1:10 000 to 1:5 (CRL-1572:MRC-5), the significant increase in the ID25 was correlated wtih the proportion of tumoral cells present in the cell inoculum. These results suggest that MTX-Phe combined with 4E3-CPA conjugate is a promising model for a more selective and localised anti-cancer chemotherapy based on the ADEPT concept.
Conventional chemotherapy regimens using methotrexate (MTX) lack both specificity and selectivity and are highly nephrotoxic. Many attempts have been made to enhance the localisation of anti-tumoral activity at the tumour site by coupling MTX to monoclonal antibodies as specific carriers to tumour antigens (Ghose et al., 1983; Kanellos et al., 1985) . Unfortunately, this approach has encountered many problems, such as a loss of pharmacological and/or immunological activity of the conjugates, a partial recognition of the targets by the conjugates due to the heterogeneity of the tumour antigens and a poor penetration of the conjugates into the tumour masses (Burstein and Knapp, 1977; Kralovec et al., 1989a, b) . Therefore, an MTX targeting model has not yet been successful in cancer therapy.
In 1987 Bagshawe et al. introduced a new concept called ADEPT (antibody-directed enzyme prodrug therapy). This two-phase system first involves the delivery of an enzyme coupled to a monoclonal antibody at the tumour site; second, a non-toxic prodrug is activated by the targeted enzyme and the drug released in the tumour vicinity is taken up by the cells (Bagshawe, 1987 (Bagshawe, , 1989 Bagshawe et al., 1988) . This approach allows the generation of large amounts of drug at the tumour site by the action of the targeted enzymes. Thus, heterogeneity in antigen expression or drug doses is no longer a limiting factor since the prodrug is ideally an inert compound. Kuefner et al. (1989) then reported that a MTX-a-peptide made up of an amino acid linked to the acarboxyl group of MTX via an amide bond can act as a prodrug, thereafter regaining its toxicity by a CPA-mediated release of free MTX in the medium (Esswein et al., 1991; Hanseler et al., 1992) .
For many years, studies in this laboratory focused on the optimisation of a drug-targeting model using MTX. With the advent of the ADEPT concept and the many interesting features related to this new strategy, efforts were made to find the most suitable MTX prodrug for CPA. As we have already reported (Perron and Page, 1994a) , an extensive synthesis and screening of 11 MTX-a-peptides selected on the basis of their polarity and structure was carried out. Since the prodrug MTX-Phe showed a cytotoxicity similar to the commercially available MTX once hydrolysed by free CPA (Perron and Page, 1994b) , these experiments led us to conclude that MTX-Phe was a potential substrate for the ADEPT system.
In order to apply these new findings to a more selective targeting model, bovine carboxypeptidase A was conjugated to the monoclonal antibody 4E3 directed against a high molecular weight glycosylated surface protein on human ovarian teratocarcinoma cells (CRL-1572) . This monoclonal antibody was characterised in this laboratory (Lemieux and Page, 1994) . A novel coupling method using an Nhydroxysuccinimidyl active ester of polyethylene glycol succinate (SS2-PEG) as the cross-linking agent was chosen for its simplicity and short reaction times. Following the purification of the conjugate preparation by gel filtration, FACS analysis confirmed the specific binding of 4E3-CPA conjugate to CRL-1572 cells. Also, 4E3-CPA conjugate retained its enzymatic activity when tested with hippuryl-Lphenylalanine.
As described in this report, we evaluated the potential of this new prodrug-enzyme combination for an application as a complete ADEPT system in vitro. CRL-1 572 cells were pretreated with 4E3-CPA conjugate followed by an exposure to prodrug MTX-Phe. A co-culture of CRL-1572 and MRC-5 cells (human normal lung diploid fibroblast cell line), which do not express the antigen targeted by the 4E3 -CPA conjugate, was also tested as a tumour mass model. (Perron and Page, 1994b) . Briefly, 1.0 mM hippuryl-L-phenylalanine in 2.95 ml of 0.1 M TrisHCl buffer pH 7.3-0.2 mM zinc sulphate was incubated at 37°C. The enzymatic reaction was initiated by adding 20 Mg of CPA contained in 50 ul, giving a final reaction volume of 3.0 ml. The increase in absorbancy was monitored with a Philips UV/Vis scanning spectrophotometer (Model PU 8720) at 254 nm for 15 min. Fractions were then passed through MAC Discs-protein G before the re-evaluation of their enzymatic activity. MAC Discs-protein G are ready-to-use purification devices purchased from Amicon (Oakville, Ontario, Canada). Recombinant protein G is linked via a very stable bond to chemically reactive affinity membranes that are inserted into a holder. Multiple passes can be accomplished by attaching a syringe to each end of the holder and gently passing the sample back and forth through the unit several times. Since CPA has no affinity for protein G, an important decrease or a total inhibition of the enzymatic activity after the sample passed through the discs is observed when CPA is linked to 4E3, which is retained on the membranes. A 0.6 dilution factor calculated for the MAC Discs-protein G unit was used to readjust the concentration of the samples before the affinity assay. The protein G membranes were prewashed with the Tris-HCl buffer used for the enzymatic assay. Samples containing 50 ,ug of each of the fractions and CPA as a control were diluted in the prewash buffer in order to obtain a final volume of 3.0 ml. Samples were then passed 40 times through the protein G unit. The enzymatic activity was then measured in the eluent as previously described. Co-culture assays The procedure described above regarding CRL-1572 cytotoxic assays was applied for the co-culture assays except for the cell inoculum. We deliberately contaminated MRC-5 cells with various amounts of CRL-1572 cells in order to simulate a tumour-like cell population. The platings were prepared as follows. Approximately 10 000 MRC-5 cells were seeded into 50 ,l of RPMI-1640-10% FBS in 96-well microtitration plates, followed immediately by the addition of CRL-1572 in various amounts ranging from 1 to 2000 cells/well also in 50 Ml of culture medium, giving a final volume of 100 ll. Cells in the co-culture platings were allowed to attach for 48 h at 37°C/5% carbon dioxide and were handled as described above for the remaining steps of the cytotoxic assay. MTX-treated cells were used as a control. Results 4E3 -CPA conjugate As described in Materials and methods, a novel procedure using (SS2)PEG 3400 was carried out to conjugate CPA to monoclonal 4E3 in replacement of the traditional crosslinking agents. The PEG active ester derivative reacts with amino groups on proteins under mild conditions within short periods of time. A molar ratio of 1 4E3: 2 CPA: 3 PEG was found optimal for the preparation of the reaction mixture in order to favour the formation of mono-(4E3:CPA), di-(4E3:2CPA) and tri-substituted (4E3:3CPA) conjugates.
When the conjugate preparation was separated on a Superose 12/30 HR column, the resulting elution profile showed three distinct peaks (Figure 1 ). The first peak, which corresponds to the void volume of the column, contained compounds having a molecular weight of 300 kDa and more (Fl 16.5-18.5 ml). A mixture of unreacted antibody (160 kDa) and material between 160 kDa and 300 kDa was recovered in the second peak (F2 18.5-20.5 ml; F3 20.5-22.5 ml). Finally, unreacted enzyme (35 kDa) and other low molecular weight components were eluted in the third peak (F4 22.5-24.5 ml; F5 24.5-26.5 ml). The calculation of an approximate yield for the conjugation reaction relied on the enzymatic activity of the fractions of interest (Fl, F2 and F3) instead of their protein content since unreacted antibody was present in fraction F3. The overall yield for the conjugation of 4E3 with CPA using PEG was evaluated at 18% and at approximately 6% for fraction F3 alone. These results do not take into account the possible loss of enzymatic activity during the conjugation process and/or the likely presence of CPA polymers in these fractions.
To obtain further information about the composition of the three major peaks, the five corresponding fractions were analysed by SDS-PAGE (Figure 2 Following these findings, a FACS analysis was carried out on the five fractions with CRL-1572 cells to evaluate the specific binding of the conjugated material contained in these three fractions. As demonstrated in Figure 3 , F3 showed a significant reactivity towards CRL-1572 cells similar to the reactivity exhibited by the monoclonal 4E3 positive control. The fluorescence intensity measured for F3 was about ten times greater than the negative control, which is purified IgG from mouse normal serum. However, the presence of unreacted 4E3 in F3 may interfere with the capacity of F3 to bind to the cells, consequently the F3 reactivity should be interpreted with caution. Fl and F2 were not as reactive as F3, their respective fluorescence intensity was similar to the control (data not shown). This indicates that high molecular 0)
.0 E Inj 12.5 16.5 20.5 24.5 28.5 32.5 Elution volume (ml) Figure 1 Elution profile following a purification on a Superose 12/30 HR column by FPLC. A 2 ml loop was required to inject the total volume (1.7 ml) of the conjugate preparation containing a total of 2 mg proteins. PBS was used as the elution buffer at a flow rate of 0.5 ml min-1. The elution was monitored at 280 nm at 0.5 AUFS. (0) Figure 5 shows that, when the cells were not treated with either one of the fractions, MTX-Phe was not cytotoxic (ID50> 1000 ng ml-'). The cytotoxicity of MTXPhe was slightly improved when the cells were initially exposed to Fl or F2, showing an IDs0 of 250 ng ml-l and 500 ng ml-' respectively. This is in accordance with the composition of these two fractions, which were characterised by FACS analysis and enzymatic assays. Fl was more active enzymatically than F2, but both fractions were not very reactive towards CRL-1572 cells, suggesting that the majority of Fl and F2 constituents had lost their immunological activity and consequently their specific binding capacity to those cells. However, when cells were pretreated with F3 before exposure to MTX-Phe, a marked reduction in growth approaching the one of MTX (ID50 15 ng ml-') could be observed. The IDs0 of MTX-Phe in these circumstances was considerably enhanced to 70 ng ml-' when compared with the initial ID50 of > 1000 ng ml-' for MTX-Phe alone. Fl, F2 or F3 treatment alone was not toxic (data not shown).
Co-culture assays with CRL-1572 and MRC-5 cells A co-culture of CRL-1572 and MRC-5cells (human normal lung diploid fibroblast cell line), which do not express the antigen targeted by the 4E3-CPA conjugate, was used as an in vitro model of a heterogeneous tumour cell population and to test the selectivity of the 4E3-CPA conjugate. MRC-5 cells were mixed in various proportions with CRL-1572 cells ranging from 1 to 2000 CRL-1572 cells per 10 000 MRC-5 cells. As described above for the cytotoxic assays, the different ratios of co-cultured cells were exposed to the conjugate, washed thoroughly and then treated with various concentrations of MTX-Phe. The same cell ratios were also treated with free MTX. As shown in Figure 6 , the cytotoxicity of MTX-Phe on the CRL-1572/MRC-5 coculture, which was initially exposed to the conjugate, decreased as the proportion of CRL-1572 cells in the Figure 6 were well below the 50% growth inhibition threshold. The ID25 measured for each curve was plotted in relation to the CRL-1572 cell number present in the co-culture inoculum (Figure 7) . (Abuchowski et al., 1984) , and the cross-linking of proteins yielding extensively modified yet active and stable conjugates in which steric hindrance is minimal with the use of' a long polyethylene spacer. The conjugation of CPA to 4E3 with (SS2)PEG 3400 in the conditions described was highly reproducible. On the other hand, the evaluation of the substitution ratio of the active material was puzzling due to the nature of the cross-linking agent used and also by the fact that both reactants (4E3 and CPA) were pooled together for the conjugation procedure. Since hydroxysuccinimide esters react with lysines, the total amount of free NH2 groups present on the proteins before and after the conjugation procedure could have been determined by the ninhydrin technique. However, this technique is not sensitive enough on low substituted material. Yet as shown by the SDS gel, the 4E3 -CPA conjugate found in fraction F3 was undoubtedly monosubstituted considering that the bands of interest in this fraction ranged from 160 kDa to 190 kDa.
The purification of 4E3-CPA conjugate was carried out in a single step. The conjugate was recovered in the third fraction (F3) following a gel filtration on a Superose 12/30 HR column. The experiments were performed with the F3 fraction, which may contain traces of impurities. The absence of free CPA in this fraction shows that the cytotoxicity reported above was related to the activity of bound 4E3 -CPA conjugate on MTX-Phe prodrug. It was shown that when CRL-1 572 were pretreated with the conjugate before an exposure to MTX-Phe, an ID50 of 70 ng ml-' could be measured, approaching that of MTX ( Figure 5 ). It was estimated that a maximum of 1.3 CPA milliunit of conjugate was delivered to each well. However, we have shown that the ID50 of MTX-Phe reached a plateau when the amount of free CPA in the culture medium exceeded 0.2 milliunits. This observation was also confirmed by Vitols et al. (1995) .
The selectivity of the 4E3-CPA/MTX-Phe combination was emphasised by a co-culture assay in which CRL-1572 cells were plated in various ratios together with MRC-5 cells, a human fibroblast cell line which is not targeted by 4E3. We decided to seed both cell lines together in order to simulate a tumour-like model in vitro instead of using co-culture inserts that eliminate contact between cells, which is less representative of the cell-cell interactions. Wilson (1984) reported that human ovarian tumour biopsies were frequently contaminated by stromal cells of fibroblastic or mesothelial origin with no change in the chemosensitivity of the culture. Figure  6 shows that 4E3-CPA/MTX-Phe had no toxic effect on MRC-5 cells alone. In addition, the cytotoxicity measured on the CRL-1572 control curve was similar to that of the 1:5 (CRL-1572:MRC-5) curve with ID50 of 70 ng ml-1 and 80 ng ml-' respectively. This suggests that only 20% antigen-positive cells was sufficient to achieve maximum cytotoxicity. Nevertheless, as few as 0.5% antigen-positive cells was sufficient to observe an increase in the cytotoxicity of MTX-Phe (Figure 7 ). Since ID25 was well correlated with the proportion of CRL-1572 in the inoculum, 4E3-CPA was undoubtedly specific to CRL-1572 cells, thus conferring selectivity to the prodrug MTX-Phe by the mediation of 4E3-CPA conjugate. These results meet one of the ADEPT concept premises, which states that heterogeneity (or absence) in antigen expression is no longer a limiting factor, a few cells need to be targeted by the conjugate to produce an amplification system allowing large amounts of drug to be liberated in the tumour vicinity and taken up by the cells regardless of their antigen expression.
Although the effectiveness of this new prodrug-enzyme combination was shown above, the 4E3-CPA conjugate will require further characterisation and improvements in order to limit the antigenicity induced by the use of the whole IgG molecule. We are presently preparing a conjugate with the Fv fragment of 4E3 for testing in a xenograft model.
